Belzutifan (WELIREG)

von Hippel-Lindau disease (including non-metastatic renal cell carcinoma, central nervous system hemiangioblastomas, and non-metastatic pancreatic neuroendocrine tumours

von Hippel-Lindau disease (including non-metastatic renal cell carcinoma, central nervous system hemiangioblastomas, and non-metastatic pancreatic neuroendocrine tumours

• Oral:  120 mg daily continuously until disease progression or unacceptable toxicity

Available as 40 mg film-coated tablets. Tablets should NOT be crushed or broken. Store at room temperature.

HIF-2alpha Inhibitor

Take with or without food

If a dose is missed, patients should be instructed to take it as soon as they can if it is remembered on the same day. Otherwise, patients should skip the missed dose and resume with the next scheduled dose.

Common: Anemia, Visual impairment, Fatigue, Glucose increase, Dizziness, Headache, Dyspnea.

Less Common: Hypoxia, Nausea, ALT increase, AST increase, Embolism, Hemorrhage.

The adverse effects listed above are not exhaustive. Please refer to the relevant product monograph for full details.

Baseline before treatment: CBC & differential, platelets, creatinine, sodium, potassium, AST, ALT, bilirubin, alkaline phosphatase, glucose, oxygen saturation, hemoglobin.

During treatment: CBC & differential, platelets, creatinine, sodium, potassium, AST, ALT, bilirubin, alkaline phosphatase, glucose, oxygen saturation, hemoglobin.

• This drug can impact or be impacted by metabolic enzymes for absorption and excretion. Many drugs can also affect or be affected by these enzymes, so please consult with pharmacy to assess for interactions.
• Current drug interaction databases should be consulted for more information.

• Avoid in pregnancy and lactation.
• Impaired wound healing is associated with belzutifan, drug may need to be held and restarted if patient requires surgery, discuss with team.
• Hypoxia can occur with belzutifan, including asymptomatic hypoxia, and may require supplemental oxygen or hospitalization. Advise patients to promptly report any signs and symptoms of hypoxia, and monitor oxygen saturation with pulse oximetry prior to treatment initiation and regularly during treatment.

Lexicomp. Belzutifan Monograph. In: Lexi-Drugs. Hudson, Ohio: Lexi-Comp, Inc. Accessed May 9, 2024.

BC Cancer. BC Cancer Drug Manual. Belzutifan. Vancouver, British Columbia: BC Cancer Agency. Available at http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Belzutifan_monograph.pdf: Updated April 1, 2024 Accessed May 9, 2024.